4 unknown, 3 completed, 2 active not recruiting, 2 recruiting. 13 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 13 | Unknown 4, Completed 3, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Terminated 1 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy REGEND007 Cell Therapy - Idiopathic Pulmonary Fibrosis (IPF) | Early Phase 1 | Not yet recruiting | Regend Therapeutics | 12 | 2026-02-15 | 2026-01-22 |
| Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis Hyperpolarized Xe129 - Idiopathic Pulmonary Fibrosis | Early Phase 1 | Recruiting | University of Virginia | 6 | 2025-05-01 | 2025-07-09 |
| A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. SV001, Placebo - Idiopathic Pulmonary Fibrosis | Early Phase 1 | Recruiting | Shanghai Synvida Biotechnology Co.,Ltd. | 53 | 2024-01-12 | 2026-08-14 |
| Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis Venetoclax - Idiopathic Pulmonary Fibrosis | Early Phase 1 | Completed | University of Alabama at Birmingham | 3 | 2023-10-01 | 2024-03-28 |
| Clinical Study of Allogeneic Fat Decellularized Active Protein in the Treatment of Pulmonary Fibrosis Cell Free Fat Extract(CEFFE) - Pulmonary Fibrosis | Early Phase 1 | Active not recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 7 | 2023-08-14 | 2025-09-19 |
| Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). Nitric Oxide, Medical air - Idiopathic Pulmonary Fibrosis | Early Phase 1 | Unknown | Dr. Denis O'Donnell | 40 | 2022-04-21 | 2024-04-03 |
| FAPI PET for Lung Fibrosis 68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography - Interstitial Lung Disease, Idiopathic Interstitial Pneumonias | Early Phase 1 | Active not recruiting | University of California, Los Angeles | 30 | 2021-11-16 | 2026-08-20 |
| Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders HP 3He, HP 129Xe, PFP - Lung Transplant, Lung Resection | Early Phase 1 | Terminated | Thunder Bay Regional Health Research Institute | 10 | 2020-11-10 | 2024-10-15 |
| Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution - Pulmonary Alveolar Proteinosis, COPD | Early Phase 1 | Unknown | Black Tie Medical, Inc. | 10 | 2020-03-25 | 2023-02-22 |
| Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. Epigallocatechin-3-gallate (EGCG) - Idiopathic Pulmonary Fibrosis | Early Phase 1 | Completed | Hal Chapman | 35 | 2017-12-01 | 2022-12-22 |
| Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT [18F]FP-R01-MG-F2 - Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis | Early Phase 1 | Completed | Stanford University | 21 | 2017-11-08 | 2025-02-04 |
| 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis 68Ga-NOTA-PRGD2, PET/CT - Pulmonary Fibrosis, Unspecified | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 30 | 2015-05-01 | 2017-04-06 |
| 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis 68Ga-BMV101 - Idiopathic Pulmonary Fibrosis | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 20 | 2015-01-01 | 2017-04-07 |
Idiopathic Pulmonary Fibrosis (9) · Lung Diseases, Interstitial (3) · Pulmonary Disease, Chronic Obstructive (2) · Alveolitis, Extrinsic Allergic (1) · Asbestosis (1) · Asthma (1) · Bronchiectasis (1) · Cholangitis, Sclerosing (1) · Coronavirus Infections (1) · Cystic Fibrosis (1) · Emphysema (1) · Hypertension, Pulmonary (1) · Idiopathic Interstitial Pneumonias (1) · Lung Injury (1)
Lung Diseases (13) · Respiratory Tract Diseases (13) · Lung Diseases, Interstitial (10) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Fibrosis (5) · Chronic Disease (2) · Digestive System Diseases (2) · Disease Attributes (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Lung Diseases, Obstructive (2) · Lung Injury (2)
Air (1) · FAPI-46 (1) · Magnetic Resonance Spectroscopy (1) · Nitric Oxide (1) · Positron Emission Tomography Computed Tomography (1) · Sulfur Hexafluoride (1) · epigallocatechin gallate (1) · perflutren (1) · venetoclax (1)
Peking Union Medical College Hospital (2) · Black Tie Medical, Inc. (1) · Dr. Denis O'Donnell (1) · Hal Chapman (1) · Regend Therapeutics (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Shanghai Synvida Biotechnology Co.,Ltd. (1) · Stanford University (1) · Thunder Bay Regional Health Research Institute (1) · University of Alabama at Birmingham (1) · University of California, Los Angeles (1) · University of Virginia (1)
United States (6) · China (5) · Canada (2)
Zhaohui Zhu, MD (2) · Denis E O'Donnell, MD (1) · Hal A Chapman, MD (1) · Henry Guo, MD, PhD (1) · Jeremie Calais, MD (1) · John Kim, MD (1) · Mitchell S Albert, PhD (1) · Robert W Alexander, MD (1)
PMID 25378391, PMID 26921108, PMID 31611594, PMID 32160670, PMID 34023385, PMID 34038004, PMID 34413485, PMID 35584850, PMID 35762891, PMID 39362770
R01HL142265 (1)